Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company... Show more
Olema Pharmaceuticals, also known as Olema Oncology, is a clinical-stage biopharmaceutical company developing therapies for women's cancers. Its lead candidate, palazestrant, is a complete estrogen receptor (ER) antagonist in two pivotal Phase 3 trials for ER-positive, HER2-negative metastatic breast cancer. Because the company generates essentially no product revenue, quarterly earnings serve primarily as a checkpoint on spending and cash runway, while the real value driver is clinical progress. With the OPERA-01 monotherapy readout expected in the first quarter of 2027, each report is scrutinized for signs of trial momentum, enrollment trends, and any shifts in timelines that could reshape the investment thesis.
Consensus estimates point to a net loss of approximately $0.64 per share for the third quarter of 2026, according to data from MarketWatch and FactSet, though some aggregators cluster near $0.60. That compares with a $0.49 loss in the same quarter a year ago, when Olema reported a net loss of $42.2 million and ended the period with $329.0 million in cash and marketable securities. Revenue expectations are negligible, reflecting the company's pre-commercial status. The widening expected loss largely reflects higher research and development (R&D) spending tied to the OPERA-01 and OPERA-02 late-stage trials and the advancement of OP-3136. In Q2 2026, Olema posted a $0.61 loss, missing the roughly $0.55 consensus, with R&D expenses climbing to $57.8 million.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Olema Pharmaceuticals alongside the broader biotechnology space, the AI Screener offers a streamlined way to surface relevant opportunities and monitor shifting technical conditions.
Sentiment heading into this report is cautious but not bearish. Olema shares have been volatile in recent months, and the stock's reaction is likely to hinge less on the loss figure itself and more on any commentary around trial timelines, data-readout schedules, and cash runway. The Q2 2026 miss underscores how operating-expense growth can outpace estimates as pivotal studies accelerate. Analysts maintain an average "Buy" rating with a target price well above current trading levels, but the wide gap between estimates on the loss per share reflects uncertainty about the pace of spending. Key risks include potential delays in the OPERA-01 readout, competitive developments in the oral selective estrogen receptor degrader (SERD) market, and any signal that the company may need additional financing before a pivotal data catalyst.
The most important catalyst on the horizon remains the OPERA-01 Phase 3 readout for palazestrant monotherapy, now expected in the first quarter of 2027. Management commentary on enrollment completion, data maturation, and any interaction with regulators will carry more weight than the quarterly loss figure.
Investors should also monitor the OPERA-02 frontline combination trial, which pairs palazestrant with ribociclib, as well as early safety and efficacy signals for OP-3136, a KAT6 (lysine acetyltransferase 6) inhibitor in Phase 1 development. Combination data expected in the first half of next year could further shape the pipeline narrative.
On the financial side, watch R&D expense trends and the company's cash position, which is widely viewed as sufficient to fund operations through the next major data catalyst. Any indication of accelerated spending or a shift in the expected data timeline would be closely scrutinized. As with most clinical-stage oncology names, the investment case hinges on binary trial outcomes rather than near-term profitability.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry Biotechnology